最近在美国召开的临床药理学和治疗学协会年度会议上报道了Merck＆Co公司的环氧合酶一2抑制剂rofecoxib（商品名Vioxx）可有效治疗中至重度疼痛。两项研究皆为18岁以上有中至重度痛经的妇女。第一项研究中127例病人以交叉形式接受单一剂量本品25或SOmg，或素普生55Omg或安慰剂 Recently reported at the annual meeting of the Association of Clinical Pharmacology and Therapeutics in the United States Merck & Co’s cyclooxygenase-2 inhibitor rofecoxib (trade name Vioxx) was reported to be effective in the treatment of moderate to severe pain. Both studies were women 18 years of age with moderate to severe dysmenorrhea. In the first study, 127 patients received either crossover doses of 25 mg or SOmg, or 55 mg of Suprudin or placebo